tracken
MannKind Corporation Aktie News
Neutral
GlobeNewsWire
●
11 Tage alt
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Neutral
Seeking Alpha
●
12 Tage alt
MannKind Corporation ( MNKD ) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 10, 2025 9:00 AM EST Company Participants Michael Castagna - CEO & Director Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Faisal Khurshid - Leerink Part...
Neutral
GlobeNewsWire
●
12 Tage alt
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring data This outcome does not impact the development of MNKD-102, MannKind's dry powder inhalation (DPI) formulation of clofazimine, which remains un...
Neutral
GlobeNewsWire
●
16 Tage alt
$100,000 in scholarship funds to be distributed to at least 10 students living with diabetes pursuing higher education in life sciences Alfred E. Mann Charities and MannKind are partnering with The Diabetes Link to launch the effort in November for Diabetes Awareness Month DANBURY, Conn.
Neutral
Seeking Alpha
●
17 Tage alt
MannKind Corporation ( MNKD ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Michael Castagna - CEO & Director Christopher Prentiss - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Yun Zhong - Wedbush Securities Inc., Research Division Brandon F...
Neutral
GlobeNewsWire
●
17 Tage alt
Q3 2025 revenues of $82.1M, +17% v. Q3 2024 YTD 2025 revenues of $237.0M, +14% v.
Neutral
GlobeNewsWire
●
24 Tage alt
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025.
Positiv
Seeking Alpha
●
etwa ein Monat alt
MannKind remains a Buy, driven by Tyvaso DPI's strong market position and Technosphere platform optionality. Tyvaso DPI continues robust growth despite Yutrepia's entry, with MNKD's Q2 share at $31 million and overall franchise strength. Recent developments include the acquisition of scPharmaceuticals, pipeline progress, and Afrezza's pediatric sBLA acceptance, supporting modest growth.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
